FNA vs. KIDS, SILK, AORT, ATRI, ATRC, TMCI, MDXG, SIBN, EMBC, and IRMD
Should you be buying Paragon 28 stock or one of its competitors? The main competitors of Paragon 28 include OrthoPediatrics (KIDS), Silk Road Medical (SILK), Artivion (AORT), Atrion (ATRI), AtriCure (ATRC), Treace Medical Concepts (TMCI), MiMedx Group (MDXG), SI-BONE (SIBN), Embecta (EMBC), and Iradimed (IRMD). These companies are all part of the "surgical & medical instruments" industry.
Paragon 28 (NYSE:FNA) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment.
Paragon 28 currently has a consensus target price of $16.75, suggesting a potential upside of 116.13%. OrthoPediatrics has a consensus target price of $45.50, suggesting a potential upside of 46.35%. Given Paragon 28's stronger consensus rating and higher possible upside, equities analysts plainly believe Paragon 28 is more favorable than OrthoPediatrics.
63.6% of Paragon 28 shares are held by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are held by institutional investors. 15.3% of Paragon 28 shares are held by insiders. Comparatively, 31.8% of OrthoPediatrics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Paragon 28 has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.
In the previous week, OrthoPediatrics had 5 more articles in the media than Paragon 28. MarketBeat recorded 24 mentions for OrthoPediatrics and 19 mentions for Paragon 28. OrthoPediatrics' average media sentiment score of 0.48 beat Paragon 28's score of -0.08 indicating that OrthoPediatrics is being referred to more favorably in the news media.
OrthoPediatrics has a net margin of -13.58% compared to Paragon 28's net margin of -24.45%. OrthoPediatrics' return on equity of -5.12% beat Paragon 28's return on equity.
OrthoPediatrics has lower revenue, but higher earnings than Paragon 28. OrthoPediatrics is trading at a lower price-to-earnings ratio than Paragon 28, indicating that it is currently the more affordable of the two stocks.
OrthoPediatrics received 277 more outperform votes than Paragon 28 when rated by MarketBeat users. However, 80.56% of users gave Paragon 28 an outperform vote while only 64.56% of users gave OrthoPediatrics an outperform vote.
Summary
OrthoPediatrics beats Paragon 28 on 11 of the 18 factors compared between the two stocks.
Get Paragon 28 News Delivered to You Automatically
Sign up to receive the latest news and ratings for FNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Paragon 28 Competitors List
Related Companies and Tools
